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| INTRODUCTION
Cancer is characterized by the accumulation of a growing body of genetic alternations and the loss of normal cellular modulation. 1 The immune system can recognize not limited solely to the classic models of self vs pathogen or self vs nonself, but also self and transformed self. 2 That is why cancer immunotherapy has demonstrated efficacy and achieved notable benefits in a variety of cancers. Several publications have demonstrated that CTLA-4 and PD-1 inhibitors as well as other immune checkpoint blockade therapies result in an increase in IFNγ production, [3] [4] [5] which in turn lead to the elimination of cancer cells. Recently, Mauguso et al 6 further
confirmed that resistance to immunotherapy is attributed to defects in IFNγ signaling. These indicate that cancer immunotherapy acts at least partially through an increase of IFNγ expression. IFNγ was first identified based on its in vitro antiviral activity. Its receptor consists of two subunits, IFNGR1 and IFNGR2. 2 The ligation to its receptor leads to the recruitment and activation of the Janus kinase, JAK1 and JAK2, which resultantly activates STAT1 and interferon regulatory factor (IRF) 1. Phosphorylated STAT1 and IRF1 translocate to the nucleus, where they bind to specific promoter elements and modulate transcription of IFNγ-regulated genes. Recently, IFNγ has been shown to have obligate roles in cancer immunology. 2 In this review, we have conducted an extensive literature search of recent 5-year studies of the roles of IFNγ signaling in the immune responses in cancer patients as well as in the tumor-bearing mice. The objective is to assess the contributions of IFNγ signaling to host protection. In the meantime, the role of IFNγ signaling in tumor escape from immune elimination is discussed. The yin and the yang of IFNγ signaling are summarized. Furthermore, IFNγ as an anticancer drug and clinical trials involving IFNγ alone or in combination with other anticancer drugs are also discussed. Thus, this review helps us to comprehensively understand the roles of IFNγ in antitumor immune response and protumor escape, which contributes to better design and management of clinical immunotherapy approaches. 16 This discrepancy could be due to cancer patient heterogeneity, tumor stage or tumor type.
| THE ROLE OF IFNγ IN IMMUNE ELIMINATION
Ionizing radiation, one of traditional cancer treatments, works primarily through the induction of tumor cell damage at a molecular level. Recently some studies have shown that the immune system is required for effective radiotherapy and IFNγ plays a pivotal role in the efficacy of ionizing radiation therapy. 17, 18 In a mouse colon cancer model, ionizing radiation therapy has no effect on tumor growth in IFNγ KO mice, but decreases tumor burden in WT mice. This could be because ionizing radiation treatment enhanced the capacity of T cells to lyse tumor cells, which is dependent on IFNγ. 17 This finding suggests that IFNγ gets involved in mediating the antitumor effects of ionizing radiation therapy. In addition, IFNγ decreases tumor cell growth by inducing tumor cell cycle arrest, apoptosis and necroptosis. In cancer types, such as breast cancer, 19 colorectal cancer 20 and hepatocellular cancer, 21 IFNγ can exert antiproliferative effect on tumor cells by enhancing expression of the cell cycle inhibitor proteins p27Kip, p16 or p21. Moreover, in colorectal cell lines, IFNγ elicits autophagy-associated apoptosis through induction of mitochondria-derived reactive oxygen species (ROS), which is dependent on cytosolic phospholipase A2 (cPLA2) activation. 22 However, in melanoma cell lines, IFNγ induces a increase in miR-29a/b, which is STAT1 dependent, but not cell cycle inhibitor proteins, and there is a negative correlation between miR-29a/b expression and the proliferation rate of various cell lines. 23 Furthermore, G1-arrest of melanoma cells induced by IFNγ requires decreased expression of cyclin-dependent kinase 6 (CDK6), which is a direct target of miR-29 in these cells. 23 In certain samples from patients with primary melanoma, but not metastatic melanoma or normal skin, the expression levels of miR-29a and miR29b are found dramatically increased, 23 suggesting that IFNγ decreased melanoma cell growth by arresting tumor cell cycle via miR-29a/b upregulation. Recently, Cekay et al 24 showed that a novel synergistic interaction of IFNγ with second mitochondria-derived activator of caspases (Smac) mimetics that antagonize x-linked Inhibitor of Apoptosis (XIAP) to induce necroptosis in apoptosis-resistant cancer cells where caspase activation is suppressed. This synergistic effect is observed in both solid and hematological cancer cell lines as well as for different Smac mimetics, indicating a broader relevance. 24 IFNγ also has to act on the tumor stroma for effective elimination of large, established tumors, although it can inhibit tumor growth by acting directly on cancer cells. Recently Kammertoens et al 25 showed that responsiveness of myeloid cells and other haematopoietic cells to IFNγ was not sufficient for tumor regression induced by IFNγ, whereas responsiveness of endothelial cells to IFNγ was necessary and sufficient for tumor regression. On the mechanism, IFNγ elicits regression of the tumor vasculature, leading to arrest of blood flow and subsequent collapse of tumors, which is like non-hemorrhagic necrosis in ischemia and unlike hemorrhagic necrosis induced by TNFα. 25 M1 macrophages enhance tumor regression, whereas M2 macrophages improve tumor progression. Monocytes-derived TAMs are the M2-polarized macrophages in most human tumors, which secrete a large amount of vascular endothelial growth factor (VEGF) to promote tumor growth. 33 IFNγ can suppress the differentiation of monocyte-derived TAMs in the tumor microenvironments and furthermore switch TAMs from M2 into M1 macrophages, which suppress VEGF secretion in vitro and in vivo and thereby inhibit angiogenesis. IFNγ exposure also switched THP-1-derived macrophages to the M1-like macrophages with enhancing pro-inflammatory capacity. 34 In a mouse model of ovarian cancer, IFNγ and GM-CSF by T cells activated TAMs to increase IL-12p40 production and augment antigen processing and presentation to tumor antigen-specific T cells. 35 Moreover, IFNγ produced by T cells, but not GM-CSF, induces macrophages to produce nitric oxide (NO) and enhances macrophage lysis of tumor cells. 35 Collectively, these data suggest that (Figure 1 ).
| THE ROLE OF IFNγ IN TUMOR ESCAPE
The above findings provide strong evidences that IFNγ plays a pivotal role in host antitumor immunity. However, IFNγ also contributes to the subsequent cancer evasion by promoting tumorigenesis and angiogenesis, eliciting expression of tolerant molecules and inducing homeostasis program ( Figure 2) . MUC16 (also known as CA125) is a high molecular weight trans-membrane mucin, a well-known biomarker for human cancers. 37, 38 MUC16 contributes to tumor development through multiple different mechanisms, such as suppressing NK cell killing capacity, reducing the sensitivity of cancer cells to drug therapy, and promoting cancer cell motility and so on. 38 Morgado et al 37 showed that IFNγ plus TNFα resulted in upregulation of MUC16 mRNA and protein in a wide spectrum of cancer cell types, but not alone, implying that this may be a general response. Furthermore, MUC16 expression is directly correlated with TNFα and IFNγ staining intensity in certain cancers. 37 These data suggest that Another tolerant molecule is IDO1, a kynurenine pathway enzyme, which is expressed by tumor cells to evade a potential effective immune response. High levels of IDO1 expression are correlated with poor prognosis in a wide spectrum of cancer types. IFNγ induces high levels of IDO1 in both human renal cell carcinoma and murine renal cell adenocarcinoma. 47 It is known that IFNγ signaling elicits apoptosis of differentiated tumor cells via STAT1. However, Liu and colleagues showed that IFNγ signaling resulted in IDO1/AhR-dependent p27 induction when IDO1 and AhR were highly expressed in tumorrepopulating cells (TRCs). 48 The p27 in turn bound to cytosolic pSTAT1, which prevented STAT1-mediated tumor cell apoptosis. Blockade of the IDO/AhR metabolic circuitry not only abrogates dormancy induced by IFNγ, but also leads to increased tumor regression. 48 49 These results link immune homeostasis to key determinants of antitumor immunity and escape, uncovering the underlying mechanism by which IFNγ contributes to tumor escape in the tumor microenvironments.
| CONCLUSION
In the context of ovarian cancer, IFNγ in combination with cyclophosphamide and cisplatin significantly prolongs progression-free survival. 50 Moreover, there are 8 ongoing clinical trials involving IFNγ alone or in combination with other anticancer drugs up to now (Table 1) . Even though it's pivotal importance in cancer immunotherapy, IFNγ has not been approved by FDA to treat patients with a variety of cancer types, except malignant osteoporosis. This could be explained by the contribution of IFNγ to tumor evasion. The yin and the yang of IFNγ signaling in cancer immunity are summarized in Figure 3 . A better understanding of the roles of IFNγ in tumor escape and tumor elimination will better design clinical immunotherapy approaches and provide new insights into cancer biology. 
